U.S. markets closed
  • S&P 500

    3,978.73
    +37.25 (+0.95%)
     
  • Dow 30

    32,120.28
    +191.66 (+0.60%)
     
  • Nasdaq

    11,434.74
    +170.29 (+1.51%)
     
  • Russell 2000

    1,799.16
    +34.34 (+1.95%)
     
  • Crude Oil

    110.74
    +0.97 (+0.88%)
     
  • Gold

    1,852.00
    -13.40 (-0.72%)
     
  • Silver

    21.97
    -0.09 (-0.42%)
     
  • EUR/USD

    1.0684
    -0.0054 (-0.50%)
     
  • 10-Yr Bond

    2.7490
    -0.0110 (-0.40%)
     
  • GBP/USD

    1.2578
    +0.0046 (+0.37%)
     
  • USD/JPY

    127.2630
    +0.4340 (+0.34%)
     
  • BTC-USD

    29,780.17
    +276.57 (+0.94%)
     
  • CMC Crypto 200

    659.93
    -11.08 (-1.65%)
     
  • FTSE 100

    7,522.75
    +38.40 (+0.51%)
     
  • Nikkei 225

    26,677.80
    -70.34 (-0.26%)
     

Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant.

  • Sera from 30 participants in the Phase 1/2 trial VLA2001-201 were used to analyze the neutralization of the ancestral SARS-CoV-2 virus and the Delta and Omicron variants.

  • All 30 samples presented neutralizing antibodies against the ancestral virus and Delta variant, and 26 samples (87%) presented neutralizing antibodies against the Omicron variant.

  • Related: Valneva's COVID-19 Vaccine Booster Works As A Follow-Up To Its Own Shot.

  • The mean fold reduction of neutralization relative to the ancestral virus was 2.7-fold for Delta and 16.7-fold for Omicron.

  • The Company continues to expect to complete regulatory submissions in Europe, the U.K., and Bahrain in time to receive potential regulatory approvals in Q1 of 2022.

  • Valneva's whole virus inactivated COVID-19 vaccine candidate uses Dynavax Technologies Corporation's (NASDAQ: DVAX) adjuvant.

  • Price Action: VALN shares are up 9.55% at $35.90 during the market session on the last check Wednesday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.